Last reviewed · How we verify
Administration of L-TC
L-TC is a therapeutic cancer vaccine designed to stimulate the immune system to recognize and attack cancer cells.
L-TC is a therapeutic cancer vaccine designed to stimulate the immune system to recognize and attack cancer cells. Used for Cancer (specific indication not publicly specified).
At a glance
| Generic name | Administration of L-TC |
|---|---|
| Sponsor | Institut de cancérologie Strasbourg Europe |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
L-TC appears to be an immunotherapeutic agent developed by Institut de cancérologie Strasbourg Europe for cancer treatment. As a phase 3 candidate, it likely works through activation of T-cell mediated immunity against tumor-associated antigens, though the specific mechanism and target antigen(s) are not publicly detailed in standard pharmaceutical databases.
Approved indications
- Cancer (specific indication not publicly specified)
Common side effects
Key clinical trials
- Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2) (PHASE1, PHASE2)
- Study of Preoperative RAdiation Therapy With Concomitant Liposomal Transcrocetin (L-TC) in Soft tISsue Sarcomas (PHASE2)
- Study of Adding or Not Liposomal Transcrocetin (L-TC) With Concomitant HypoFractionated Radiation ThErapy and TEmozolomide in Newly Diagnosed GLioblastoma (GBM) Patients (PHASE3)
- A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis (PHASE1)
- Russian Familial Hypercholesterolemia Registry
- F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Administration of L-TC CI brief — competitive landscape report
- Administration of L-TC updates RSS · CI watch RSS
- Institut de cancérologie Strasbourg Europe portfolio CI